# A Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of NKF-PEG, and US-Neulasta in Healthy Adult Male Volunteers

> **NCT07738991** · PHASE1 · RECRUITING · sponsor: **Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.** · enrollment: 202 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** NKF-PEG
- **BIOLOGICAL:** US-Neulasta

## Key facts

- **NCT ID:** NCT07738991
- **Lead sponsor:** Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-03
- **Primary completion:** 2026-11-09
- **Final completion:** 2027-04-12
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738991, "A Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of NKF-PEG, and US-Neulasta in Healthy Adult Male Volunteers". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07738991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*